The recent development of immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) has contributed to improvements in the prognosis of many patients with advanced NSCLC [2, 3]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.